FREMANEZUMAB

Brand name:

• Ajovy®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Chronic migraine

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (Major)

Comment:

Deferred from November 2019 PBAC Meeting

Submission sponsor:

Teva Pharma Australia Pty Ltd

Other PBAC consideration:

• FREMANEZUMAB

Submission received for:

March 2020 PBAC meeting

Opportunity for consumer comment:

Open 24/12/2019 and close 12/02/2020 (see PBS Website)

PBAC meeting:

Held on 11/03/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

20/04/2020

Lodgement of required documentation:

22/05/2020

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 18/06/2021

Status:

Finalised

Government processes:

Commenced on 18/06/2021

Medicine listed on the PBS:

01/08/2021 (see PBS schedule)

---